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ABSTRACT
Objective To investigate whether filaggrin gene defects,
present in up to one in 10 western Europeans and North
Americans, increase the risk of developing allergic
sensitisation and allergic disorders.
Design Systematic review and meta-analysis.
Data sources Medline, Embase, ISI Science Citation
Index, BIOSIS, ISI Web of Knowledge, UK National
Research Register, clinical trials.gov, the Index to Theses
and Digital dissertations, and grey literature using
OpenSIGLE.
Study selection Genetic epidemiological studies (family,
case-control) of the association between filaggrin gene
defects and allergic sensitisation or allergic disorders.
DataextractionAtopiceczemaordermatitis,foodallergy,
asthma, allergic rhinitis, and anaphylaxis, along with
relevant immunological variables relating to the risk of
allergic sensitisation as assessed by either positive skin
prick testing or increased levels of allergen specific IgE.
Data synthesis 24 studies were included. The odds of
developing allergic sensitisation was 1.91 (95%
confidenceinterval1.44to2.54)inthefamilystudiesand
1.57 (1.20 to 2.07) in the case-control studies. The odds
of developing atopic eczema was 1.99 (1.72 to 2.31) in
the family studies and 4.78 (3.31 to 6.92) in the case-
control studies. Three studies investigated the
associationbetweenfilaggringenemutationsandallergic
rhinitis in people without atopic eczema: overall odds
ratio 1.78 (1.16 to 2.73). The four studies that
investigated the association between filaggrin gene
mutations and allergic rhinitis in people with atopic
eczema reported a significant association: pooled odds
ratio from case-control studies 2.84 (2.08 to 3.88). An
overall odds ratio for the association between filaggrin
genemutationsandasthmainpeoplewithatopiceczema
was 2.79 (1.77 to 4.41) in case-control studies and 2.30
(1.66 to 3.18) in family studies. None of the studies that
investigated filaggrin gene mutations and asthma in
people without atopic eczema reported a significant
association; overall odds ratio was 1.30 (0.7 to 2.30) in
the case-control studies. The funnel plots suggested that
publication bias was unlikely to be an explanation for
these findings. No studies investigated the association
between filaggrin gene mutations and food allergy or
anaphylaxis.
Conclusions Filaggrin gene defects increase the risk of
developing allergic sensitisation, atopic eczema, and
allergicrhinitis.Evidenceof therelationbetweenfilaggrin
gene mutations and atopic eczema was strong, with
people manifesting increased severity and persistence of
disease. Filaggrin gene mutations also increased the risk
of asthma in people with atopic eczema. Restoring skin
barrier function in filaggrin deficient people in early life
may help prevent the development of sensitisation and
haltthedevelopmentandprogressionofallergicdisease.
INTRODUCTION
Atopic diseases, including eczema (atopic dermatitis),
asthma, and allergic rhinitis have increased in preva-
lence in recent decades and now affect up to one in
three children in economically developed
countries.
12 These conditions are responsible for
appreciable morbidity and costs, both to people and
to the state.
34The prevalence of these disorders varies
worldwide and when coupled with data showing
changes in prevalence over time points to the causal
role of environmental factors. The key implication of
thisepidemiologicalevidenceisthatatopicallergicdis-
orders should in principle be largely preventable.
5
The clinical cause of atopic disorders has been
describedasanatopicorallergicmarch.Thisconcerns
sensitisation to food or aeroallergens, or both, in early
life, progressing to eczema and wheeze within the first
two years of life, and often leading to chronic asthma,
rhinitis, and other clinical manifestations of atopic
allergy in later life.
Recent reports have suggested a key role of the pro-
tein filaggrin in maintaining an effective skin barrier
against the environment.
6 Mutations in the profilag-
grin gene resulting in loss of function are common,
being present in up to 10% of western European and
North American populations. This is of potential
importance given that rapid screening for filaggrin
gene defects is now possible through analysis of cord
or fetal blood specimens or, in older infants, using
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Trial, design, and setting
No of
participants Age (years) Genotype Outcome measures Diagnostic method or criteria Confounders Quality
Barker et al 2007
w10
(case-control, England):
Cases from hospital dermatology
clinics;populationbasedcontrols
(British ancestry)
163cases,1463
controls
Cases 36.4
(range 16-82)
R501X and
2282del4
Primary outcome persistent atopic
dermatitis (present since early
childhood)
UK Working Party definition as
interpreted by experienced
dermatologist
Matched for
ethnicity
B
Bisgaard et al 2008
w20 (cohort,
Denmark and England):
Copenhagen Prospective Study
on Asthma in Childhood
(COPSAC): high risk birth cohort
379 NA R501X and
2282del4
Primary outcome age at onset of
eczema; secondary outcomes
allergic sensitisation: specific IgE
>0.35KU/l to range of common
inhalant and food allergens
(environmental exposures
included pet ownership)
Eczema (Hanfin and Rajka criteria) Matched for
ethnicity and
age
B
Manchester Asthma and Allergy
Study: unselected population
based birth cohort
503 NA R501X and
2282del4
Primary outcome age at onset of
eczema; secondary outcomes
allergic sensitisation and
environmental exposure
Informationoneczemacollectedby
age 1 using interviewer
administered validated
questionnaire of International
Study on Asthma and Allergies in
Childhood; sensitisation assessed
using skin prick tests
Matched for
ethnicity and
age
B
Brown et al (2008)
w19
(case-control, England):
CasesfromLondonandNewcastle
upon Tyne; controls from
unselectedbirthcohortfromnorth
west
186cases,1035
controls
— R501X,
2282del4,
R2447X,
S3247X,
3702delG,
and
3673delC
Primary outcome early onset and
persistent atopic dermatitis
(present since early childhood)
Phenotypic characteristics as
reported by Barker et al
w10
Matching for
ethnicity, age,
and sex
unclear
C
Brown etal(2008)
w22 (case-control,
north west England):
Participants from population
cohort with DNA samples
collected at birth, representing
>85%ofdeliveriesinonehospital,
1996-2003
190 cases, 599
controls
7-9 R501X,
2282del4,
R2447x,
S3247X,and
3702delG
Primary outcome mild to moderate
atopic dermatitis; other outcomes
asthma with and without eczema
andallergicrhinitiswithouteczema
Eczema cases defined using UK
diagnostic criteria and skin
examination by dermatologist;
cases of asthma and seasonal
rhinitis defined by parental
questionnaire
Matched for
ethnicity and
age
B
Enomoto et al (2008)
w21 (case-
control and family study, Japan):
Participants from Japanese
population; controls had no
history of allergic disease
376 cases, 923
controls
Cases mean
29.7(range16-
64), controls
mean 46.2
(range 19-78)
S2554X and
3321delA
Primaryoutcomeatopicdermatitis;
other outcomes raised total serum
IgE level, early onset atopic
dermatitis (<2 years)
Atopic dermatitis (Hanifin and
Rajka criteria)
Unclear B
Families from dermatology
departments, University Hospital
ofTsukuba, andseveral hospitals
in Ibaraki
105 families Probands and
siblings mean
13.3 (range
0.9-42)
S2554X and
3321delA
Atopic dermatitis Hanifin and Rajka criteria Unclear B
Ekelund, et al (2008)
w24
(family study, Sweden)
Families from dermatology
departments, Karolinska
University Hospital and Danderyd
Hospital, Stockholm
406 families Siblings mean
29
R501X and
2282del4
Atopic eczema, asthma with
eczema,allergicrhinoconjunctivitis
with eczema, and total IgE level
Diagnosed by same dermatologist,
based on clinical examination and
according to UK Working Party
criteria; doctor diagnosed asthma
or allergic rhinitis
Matched for
ethnicity and
adjusted for
sex
B
Giardina et al (2008)
w14
(case-control, Italy)
Cases from trios analysed in
previous research or screening of
newly recruited patients with
atopic dermatitis; controls were
blood donors without history of
psoriasis, atopic dermatitis, or
other autoimmune disorder
178 cases, 210
controls
— R501X and
2282del4
Atopic dermatitis Diagnosis by expert dermatologist
or paediatric allergologist
Matched for
ethnicity
C
Howell et al (2007)
w2
(case-control, USA):
CasesrecruitedaspartofNational
InstitutesofAllergyandInfectious
30 cases, 39
controls
Cases mean
36.2 (SD 1.8),
R501X and
2282del4
Atopic dermatitis Diagnostic method unknown C
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No of
participants Age (years) Genotype Outcome measures Diagnostic method or criteria Confounders Quality
Disease funded Atopic Dermatitis
and Vaccinia Network
controls mean
36.8 (SD) 2.1
Matched for
ethnicity and
age
Hubiche et al (2007)
w13
(case-control, France):
Cases from department of
dermatology,BordeauxUniversity
Hospital, controls from French
population
99 cases, 102
controls
Cases median
7( r a n g e
2 months to
68 years)
R501X
an-
d2282del4
Atopic dermatitis UK Working Party criteria, trained
dermatologist did complete
examination, registered doctor
diagnosed asthma, disease
severity using SCORAD, total IgE
level using CAP system
Matched for
ethnicity
B
Lerbaek et al (2007)
w9
(case-control, Denmark):
Cohort of twins born 1953-76,
living on Zealand or neighbouring
islands, drawn from Danish twin
registry, inclusion criterion was
self reported hand eczema;
controls from COPSAC, exclusion
criteria atopic dermatitis
183 in cohort,
189 controls
Mean 41 (SD
6.6)
R501X and
2282del4
Primary outcome hand eczema;
other outcomes contact allergy,
atopic dermatitis
Hand eczema diagnosed on basis
of positive answer to question, UK
Working Party’s criteria used to
define whether participants had
ever had atopic dermatitis, patch
testing for contact allergy
Matched for
ethnicity
C
Marenholz et al (2006)
w12 (family
study and case-control, Europe):
Genetic Studies in Nuclear
Families with Atopic Dermatitis
(GENUFAD) cohort; inclusion
criteria moderate to severe
eczema
490 families,
including 903
children with
eczema
Children mean
7.9
R501X and
2282del4
Primary outcome atopic dermatitis
(age at onset <2 years); subgroups
—atopic dermatitis with asthma,
atopic dermatitis with allergic
rhinitis, other outcomes (raised
specific IgE levels)
Eczema (Hanfin and Rajkacriteria),
children whose parents reported
doctor diagnosed asthma or hay
fever were defined as having
asthma or allergic rhinitis,
respectively; allergic sensitisation
defined as presence of specific IgE
to at least one tested allergen of
>0.70 kU/l, severe to moderate
disease defined by objective
SCORAD >15
Matched for
ethnicity
A
German Multicenter Allergy Study
(MAS)cohort;controls,repeatedly
and consistently documented
absenceofsignsandsymptomsof
allergic disease
871 DNA
samples, 189
cases with
eczema, 321
controls
— R501X and
2282del 4
No explicit primary outcome;
clinical outcomes atopic
dermatitis, asthma with and
without eczema, allergic rhinitis
with and without eczema, other
outcomes (raised specific IgE
levels)
Doctordiagnosedeczema,parental
report of eczema symptoms, or
visibleeczemaattimeoffollow-up;
asthma (≥1 wheeze episodes
during past year at age 7 or 10)
Matching for
age and
ethnicity
unclear
B
Morar et al (2007)
w8 (family study
and case-control, London):
Families recruited through
children with active atopic
dermatitis from tertiary referral
centre: dermatology clinics at
Great Ormond Street Hospital for
Children (ECZ1 panel), children
represent most severe end of
disease spectrum
148 families Median 6.89
(SD 0.270)
R501X and
2282del4
No explicit primary outcome;
clinical outcomes atopic
dermatitis, asthma with atopic
dermatitis; sensitisation outcome
atopy (positive skin prick test
response ≥3m mt h a nn e g a t i v e
control,positivespecificIgE,raised
total serum IgE level, or any
combination of these features)
Atopic dermatitis (Hanifin and
Rajka criteria) defined by UK
Working Party; for asthma and
allergicrhinitisquestionsbasedon
American Thoracic Society
questionnaire; each family
examined by doctor
Matched for
ethnicity
B
Details as above (MRCE panel) 278 families Median 6.7
(SD 0.21)
R501X and
2282del4
Details as above Details as above Matched for
ethnicity
B
Details asabove (ECZ1 and MRCE
panels)
426 families — R501X and
2282del4
Details as above Details as above Matched for
ethnicity
B
Cases and controls from families
recruitedfromdermatologyclinics
at Great Ormond Street Hospital
for Children
426familieswith
990affectedand
unaffected
children; 426
cases, 564
controls
— R501X and
2282del4
No explicit primary outcome;
clinicaloutcomesatopicdermatitis
and asthma without atopic
dermatitis
Details as above Matched for
ethnicity
B
Nomuraetal(2007)
w7(case-control,
Japan):
Cases from independent
Japanese families; controls were
unrelated individuals
143 cases, 156
controls
— R501X,
2282del4,
3702delG,
S2554X,and
3321delA
Atopic dermatitis Atopic dermatitis (Hanifin and
Rajka criteria)
Matched for
ethnicity
B
Nomura et al (2008)
w18
(case-control, Japan):
Japanese cases and controls 102 cases, 133
controls
— S2554X,
S2889X,
Atopic dermatitis Diagnosedbydermatologistsusing
Hanifin and Rajka criteria
Matched for
ethnicity
B
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S3296X,and
3321delA
Palmer et al (2006)
w1 (case-control,
Ireland, Scotland, Denmark):
Cases from hospital dermatology
clinics, control Irish population
52 cases, 189
controls
Cases: wild
type7(range1-
16), filaggrin
gene null
heterozygotes
4 (range1-11),
filaggrin gen
null
homozygotes:
8( r a n g e2 - 1 2 )
R501X and
2282del4
Atopic dermatitis Hanifin and Rajka criteria and UK
working party definition), severity
assessed using validated
Nottingham eczema severity score
Matched for
ethnicity
B
Cases form BREATHE study,
Scotland; controls Scottish
schoolchildren (both recruited
from Tayside area, north east
Scotland)
604cases,1008
controls
Cases: wild
type 10.4
(range 2.7-
21.2), filaggrin
gene null
heterozygote
10.2 (range
4.1-22.0),
filaggrin gene
null
homozygote
9.28 (range
4.5-12.8)
R501X and
2282del4
Primary clinical outcome asthma;
other outcome atopic dermatitis
with asthma
Asthma diagnosed by doctors
according to Scottish
Intercollegiate Guidelines
Network/British Thoracic Society
diagnostic guidelines; in addition,
parentswereasked “Has yourchild
ever had eczema or an itchy rash?”
Matched for
ethnicity
B
Cases and controls from COPSAC 142 cases, 190
controls
— R501X and
2282del4
Clinicaloutcomesatopicdermatitis
with and without asthma
Development of atopic dermatitis
a n da s t h m au pt oa g e3y e a r s
monitored prospectively by clinical
follow-up and diary card with
complete follow-up data; atopic
dermatitis (Hannifin and Rajka
criteria)
Matching for
ethnicity and
age unclear
B
Palmer et al (2007)
w11
(cross sectional, Scotland):
Cohort from BREATHE study of
childhood asthma
874 Mean10.4(SD
4.0), range 3-
22
R501X and
2282del4
Asthma severity: mean forced
expiratory volume in one second/
forced vital capacity (airway
obstruction), prescribed drugs,
British Thoracic Society asthma
treatment step, rescue drug use,
inhaled bronchodilator
Doctor diagnosed asthma, British
Thoracic Society guidelines used
for severity. Ratio of forced
expiratory volume inone secondto
forced vital capacity used as
measure of airway obstruction for
severity,eczemastatusdetermined
using question, does child have
eczema?
Matching for
ethnicity, age,
and sex
unclear
B
Rogers et al (2007)
w6
(family study, North America):
Families from Childhood
Management Asthma Program
(CAMP)
646 probands,
460 complete
families
Patients with
atopic
dermatitis 8.5
(SD 2.2),
patients
without atopic
dermatitis 9.0
(SD 2.1)
R501X and
2282del4
Clinical outcomes asthma without
atopic dermatitis, asthma with
atopic dermatitis, asthma severity,
sensitisation(atopy,totalIgElevel)
Diagnosis of asthma based on
methacholine hyper-reactivity and
≥1 of following criteria for at least
6 months in year before
recruitment: asthma symptoms at
leasttwiceaweek,atleasttwouses
a week of inhaled bronchodilator,
or daily asthma drug; diagnosis of
atopic dermatitis based on
affirmative response to question,
“Has your child ever had atopic
dermatitis for 2 years?”
Matched for
ethnicity and
age
B
Ruether et al (2006)
w15
(case-control and family study,
northern Germany):
Cases from dermatological
outpatient ward, controls from
PopGen Project
272 cases, 276
controls
Cases median
10
R501X and
2282del4
Atopic dermatitis Hanifin and Rajka criteria Matched for
ethnicity
B
Families recruited from
dermatological outpatient ward
338 families Median 10 R501X Atopic dermatitis Hanifin and Rajka criteria Matched for
ethnicity
B
Sandilands et al (2007)
w3
(case-control, Ireland):
Cases from hospital based
paediatric dermatology clinic,
controls children sampled by
cheek swab at dispersed centres
188 cases, 736
controls
Cases mean
4.9
R501X,
2282del4,
R2447X,
Atopic dermatitis Dermatologist diagnosed
moderate to severe atopic
dermatitis using UK Working Party
criteria
Matched for
ethnicity
B
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cant cost (<£100; €117; $164).
Lack of expression of the protein filaggrin has been
shown to predispose to the development of ichthyosis
vulgaris and, more recently, atopic eczema or
dermatitis.
67 The filaggrin gene resides on human
chromosome 1q21 within the epidermal differentia-
tion complex, a region that also harbours genes for
severalotherproteinsthatareimportantforthenormal
barrier function of the epidermis.
8 The primary func-
tionoffilaggrinseemstobetoaggregatetheepidermal
cytoskeleton to form a dense protein-lipid matrix
thereby regulating permeability of the skin to water
and external particles such as allergens.
9
Information about the association between filaggrin
gene defects and allergic disorders is accruing rapidly.
The initial focus was atopic eczema, which has been
investigated in several studies, but to what extent do
filaggrin gene defects increase this risk, and what
impact, if any, do they have on the risk of developing
otherallergicdisorders?
10-13Fromfirstprinciples,these
genedefectsshouldalsoincreasetheriskofdeveloping
pathophysiologically related conditions such as food
allergy, allergic rhinitis, and asthma. This was, for
Trial, design, and setting
No of
participants Age (years) Genotype Outcome measures Diagnostic method or criteria Confounders Quality
S3247X,and
3702delG
Stemmler et al (2007)
w17
(case-control, Germany):
Unrelated cases recruited by
consultant specialist, controls
recruited by same doctor or at
University Hospital of Essen
378 cases, 700
controls
Cases 7.25
(range0.5-72),
controls 50.2
(range 19-87)
R501X and
2282del4
No explicit primary outcome;
clinical outcomes atopic
dermatitis; subgroups atopic
dermatitis onset age <18 years and
onset age <2 years
Atopic dermatitis (Hanifin and
Rajka criteria)
Matched for
ethnicity
B
Sugiura et al (2005)
w5
(case-control):
Source of participants unknown 17 cases, 4
controls
Cases mean
27, controls
mean 34
Filaggrin
gene
Atopic dermatitis Diagnostic criteria of Williams et al Unclear C
Weidinger et al (2006)
w4
(family study, Germany):
White population, Munich and
Bonn
476 families Offspring:
22.12 (SD
10.76),
parents 54.71
(SD 10.27)
R501X and
2282del4
No explicit primary outcome;
clinicaloutcomesatopicdermatitis
with or without asthma; other
outcomes allergic sensitisation,
total IgE level
Atopic dermatitis diagnosed on
basis of skin examination by
dermatologist using UK Working
Party diagnostic criteria for atopic
dermatitis, doctor diagnosed
asthma or allergic
rhinoconjunctivitis, specific
sensitisation (presence of at least
one specific IgE antibody)
Matched for
ethnicity
B
Weidinger et al (2007)
w16
(case-control, Germany):
Cases from dermatology
outpatient departments of
university of Bonn and Technical
university Munich. population
based controls from KORA S4,
south Germany
274 cases, 252
controls
Cases35.9(SD
10.8), controls
39.4 (SD 16.1)
R501X and
2282del4,
No explicit primary outcome;
clinical outcomes atopic
dermatitis, early onset atopic
dermatitis (age <2 years), atopic
dermatitis with asthma, atopic
dermatitis with allergic rhinitis,
severity of atopic dermatitis
(SCORAD), other outcomes (total
IgE level)
Atopicdermatitis(UKWorkingParty
diagnostic criteria), severity of
eczema assessed using SCORAD,
doctor’s diagnosis of asthma or
allergicrhinoconjunctivitis,specific
sensitisation (presence of at least
one specific IgE antibody)
Matched for
ethnicity;odds
ratiosadjusted
forageandsex
B
Weidinger et al (2008)
w23
(cross sectional, Germany):
Participants from cross sectional
population of German children
recruited as part of International
Study of Asthma and Allergies in
ChildhoodII,MunichandDresden
Cross sectional
population
(n=3099)
9-11 R501X,
2282del4,
R2447X,
S3247X,and
3702delG
Clinicaloutcomeseczemaoratopic
eczema, allergic rhinitis with and
without atopic eczema, asthma
with and without atopic eczema,
sensitisation
Children whose parents reported
doctor diagnosed endogenous or
atopicdermatitiswereclassifiedas
having eczema; eczema divided
intoatopiconbasisofpositiveskin
prick test against at least one
allergen tested, children with
doctor diagnosed asthma in self
administered questionnaire were
classified as having asthma,
definition of allergic rhinitis based
on parent’s information of doctor
diagnosedhayfeverincombination
withpositiveskinpricktestagainst
at least one allergen tested
Matched for
ethnicity and
age
B
SCORAD=scoring atopic dermatitis; KORA-S4=Cooperative Health Research in the Region of Augsburg Survey 4
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model of atopic eczema, which found that dysfunction
of the skin barrier not only enhances sensitisation to
allergens but also leads to systemic allergic responses
such as increased IgE levels and airway
hyperreactivity.
14 These observations support the
idea that absorption of allergens through the skin of
patients with atopic eczema may predispose to the
development of other allergic conditions.
We undertook a systematic review and meta-analy-
sis to investigate the relation between filaggrin gene
mutations, allergic sensitisation, and development of
a range of atopic allergic disorders—namely, food
allergy, eczema, asthma, allergic rhinitis, and anaphy-
laxis.
METHODS
We considered as eligible for inclusion any type of
genetic epidemiological study in humans of all ages
and ethnic groups that investigated the association
between filaggrin gene defects and allergic sensitisa-
tion or allergic disorders. Case studies were excluded.
The clinical outcome measures of interest were atopic
eczemaordermatitis,foodallergy,asthma,allergicrhi-
nitis, and anaphylaxis, along with relevant immunolo-
gical variables relating to the risk of allergic
sensitisation as assessed by either positive skin prick
testing or increased levels of allergen specific IgE.
Search strategy
We searched Medline, Embase, ISI Science Citation
Index, and BIOSIS databases from their inception to
31 December 2008. Our searches were not restricted
by language, age, sex, or publication type. Search
terms were “filaggrin”,O R“profilaggrin”,O R
“1q21”,O R“epidermal differentiation complex”,
OR “R501X”,O R“2282del4”,O R“3321delA”,O R
“S2554X” AND “allergy”,O R“asthma”,O R“food
allergy”,O R“atopic dermatitis”,O R“eczema”,
“rhinitis”,O R“anaphylaxis”,O R“sensitisation”,O R
“epidermaldysfunction”(seewebextraappendix1for
the detailed search strategy). We checked the biblio-
graphiesofincludedstudiesforadditionalstudies,sup-
plementedwithacitationsearchofreferencesusingISI
Web of Knowledge.
Using the UK National Research Register, clinical
trials.gov,andtheIndextoThesesandDigitaldisserta-
tions we searched for details of unpublished, ongoing
studies. We also used OpenSIGLE to search for grey
literature.
Study selection, quality assessment, data extraction, and
statistical analysis
Two reviewers scanned the identified articles on the
basis of the title, key words, and abstract (when avail-
able).Articleswererejectedontheinitialscreenifthey
failed to meet our inclusion criteria. When a title or
abstract could not be rejected with certainty, the
reviewers obtained a full text copy of the article for
evaluation.Thefulltextversionsofallrelevantarticles
identifiedbyasearchofreferenceswerealsoobtained.
Two reviewers then assessed the eligibility of studies
for inclusion in the review. Any disagreements were
resolved by discussion.
Drawing on published guidelines for the quality
assessment of genetic epidemiological studies, we
developed a customised checklist for assessing the
quality of the studies, considering the key variables of
participant selection, validity of the approach to geno-
typing, population stratification, and other statistical
considerations(seewebextraappendix2).
1516Wecon-
tacted the authors of studies for missing information.
On the basis of our assessment and prioritising the
importance of internal validity, we classified studies
as being of high, medium, or poor quality depending
on the overall risk of drawing biased conclusions.
Data on the participants, study design, genetic poly-
morphisms, outcome measures, and associations were
extractedusingacustomiseddataextractionsheet.We
used Review Manager 4.2 (Cochrane Collaboration)
and Comprehensive Meta-analysis, version 2 to ana-
lyse the data. Asthe two common filaggrin gene muta-
tions R501X and 2282del4 are believed to have
equivalent biological effects most of the studies ana-
lysed for a combined genotype effect along with an
analysis of the two most common filaggrin gene muta-
tions. In our meta-analyses we initially focused on the
effects of these two common mutations separately and
then combined.
We evaluated an overall estimate for the different
outcomes for case-control studies and for family stu-
dies separately.
1516 When necessary in case-control
studies we calculated the odds ratios for filaggrin car-
riers comparedwith non-carriers.We usedthe normal
approximation of the Mantel-Haenszel statistic.When
therewasazerointhecontingencytableweadded0.5.
Tocalculatethe confidenceintervalsforfamilystudies
we used the formula standard error (log odds ratio)
=√(1/T+1/U) (see web extra appendix 3 for a fuller
explanation).
Potentially relevant papers identified from searches
of databases and screened for retrieval (n=319)
Retrieved for more detailed evaluation after
scanning titles and abstracts (n=123)
Potentially appropriate papers  (n=28)
Articles included in systematic review  (n=24)
Papers not relevant (n=196)
Excluded as only reported as abstracts  (n=4)
Papers excluded (n=95):
  Not a genetic epidemiology study (n=42)
  Duplicate publication (n=5)
  Case study (n=1)
  Other topic (n=18)
  Animal study (n=3)
  Congress report (n=12)
  Other (n=14)
Fig 1 | Selection of studies
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ratios. Study heterogeneity was investigated using the
I
2 statistic. If heterogeneity was detected, we investi-
gated this by undertaking subgroup analyses when
possible, focusing on the impact of study quality and
disease severity as explanatory factors. Possible publi-
cationbiaswasassessedgraphicallyusingfunnelplots.
When it was not appropriate or possible to undertake
meta-analyses, we described the data using a narrative
approach.
RESULTS
Overall, 24 of 319 identified papers were eligible for
inclusion.
w1-w24 No studies were identified that investi-
gated the association between filaggrin gene defects
and the risk of developing food allergies or
anaphylaxis.Figure1describesthestudyselectionpro-
cess, and the table lists the characteristics of the
included studies.
Sensitisation
Two case-control analyses
w12 w23 and seven familial
analyses (reported in four papers)
w4 w6 w8 w12 investi-
gated the association between filaggrin gene defects
and allergic sensitisation (see web extra table A).
Case-control studies
Pooled data from the two case-control studies
w12 w23
gave an overall odds ratio for the combined genotype
of 1.57 (95% confidence interval 1.20 to 2.07; fig 2).
Heterogeneity was significant (P=0.001) but could not
be investigated owing to the small number of studies.
Family studies
One family study
w8 analysed two different family
panels and presented results for each panel as well as
for the panels combined. One family study
w6 reported
P values only and therefore was not included in the
meta-analysis.
Pooled data for the combined genotype from the
other family studies gave an overall odds ratio of 1.91
(1.44 to 2.54; fig 2). Heterogeneity was significant
(I
2=72.20;P<0.001).Thefunnelplotshowedasymme-
trical inverted shape, suggesting there was no major
publication bias (see web extra fig A).
The overall odds ratio for the filaggrin gene muta-
tion R501X was 2.47 (1.70 to 3.59; fig 2) and for the
filaggrin gene mutation 2282del4 was 2.25 (1.85 to
2.75; fig 2). Heterogeneity was not significant (P=0.11
and P=0.83, respectively).
Atopic eczema and atopic dermatitis
Twenty case-control analyses
w1-w3 w5 w7-w10 w12-w19 w21-w23
and eight familial analyses
w4 w8 w12 w15 w21 w24 investi-
gated the association between filaggrin gene defects
andatopicdermatitis.Mostofthestudieswereonwes-
tern European populations, but three case-control stu-
dies
w7 w18 w21 and one family study
w21 were on a
Japanese population and one case-control study
w2 was
on a North American population.
Case-control studies
See web table B for details of the case-control studies.
The study by Sugiura et al was the first to describe the
association between filaggrin and atopic dermatitis.
w5
It found down-regulation of the cornified envelope
genes like filaggrin in the skin of people with atopic
dermatitis (P=0.035). This study was not included in
the meta-analysis because it was not possible to calcu-
late an odds ratio and 95% confidence interval. Four
other case-control studies
w7 w8 w18 w21 were also not
included in the meta-analysis. Three studies were on
a Japanese population and the most common Eur-
opean filaggrin gene mutations R501X and 2282del4
were absent in 253 participants.
w7 w18 w21 Novel filag-
grin gene mutations were, however, noted in the Japa-
nese population and a statistical association was found
  Marenholz 2006w12
  Weidinger 2008w23
Total (95% CI)
Test for heterogeneity: df(Q)=1,
  P=0.001, I2=0%, z=3.280
1.41 (0.70 to 2.80)
1.61 (1.20 to 2.17)
1.57 (1.20 to 2.07)
0.01 0.1 1 10 100
Case-control studies
Combined genotype
Odds ratio
(95% CI)
Odds ratio (random)
(95% CI)
  Marenholz 2006w12
  Weidinger 2006w4
  Morar (ECZ1 panel) 2007w8
  Morar (MRCE panel) 2007
w8
  Morar (combined panel) 2007
w8
Total (95% CI)
Test for heterogeneity: df(Q)=4,
  P=0.006, I2=72.203%, z=4.44
2.49 (1.86 to 3.34)
3.04 (1.95 to 4.73)
1.76 (1.15 to 2.69)
1.38 (1.00 to 1.90)
1.51 (1.16 to 1.95)
1.91 (1.44 to 2.54)
0.1 0.5 0.2 1 5 21 0
Odds ratio
(95% CI)
Odds ratio (random)
(95% CI)
Family studies
  Marenholz 2006w12
  Weidinger 2006
w4
  Morar (MRCE panel) 2007
w8
  Morar (combined panel) 2007w8
Total (95% CI)
Test for heterogeneity: df(Q)=3,
  P=0.109, I2=50.409%, z=4.77
2.09 (1.26 to 3.48)
7.20 (2.83 to 18.35)
2.11 (1.34 to 3.34)
2.19 (1.48 to 3.25)
2.47 (1.70 to 3.59)
0.01 0.1 1 10 100
Filaggrin R501x mutation Odds ratio
(95% CI)
Odds ratio (random)
(95% CI)
  Marenholz 2006
w12
  Weidinger 2006w4
  Morar (ECZ1 panel) 2007w8
  Morar (MRCE panel) 2007
w8
  Morar (combined panel) 2007w8
Total (95% CI)
Test for heterogeneity: df(Q)=4,
  P=0.832, I2=0%, z=7.99
2.38 (1.70 to 3.33)
2.24 (1.40 to 3.59)
2.85 (1.51 to 5.35)
1.75 (1.01 to 3.03)
2.18 (1.45 to 3.29)
2.25 (1.85 to 2.75)
0.1 0.5 0.2 1 5 21 0
Odds ratio
(95% CI)
Odds ratio (random)
(95% CI)
Filaggrin 2282del4 mutation
Fig 2 | Association between filaggrin combined genotype (≥1 mutation) and sensitisation in
case-control and family studies and between filaggrin gene mutations R501X and 2282del4
and sensitisation in family studies
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  Marenholz 2006w12
  Palmer (Denmark) 2006w1
  Palmer (Ireland) 2006w1
  Barker 2007
w10
  Lerbaek 2007w9
  Sandilands 2007w3
  Stemmler 2007w17
  Weidinger 2007w16
  Brown 2008w19
  Weidinger 2008w23
  Brown 2008w22
Total (95% CI)
Test for heterogeneity: df(Q)=10,
  P=0, z=8.31
3.73 (1.98 to 7.02)
2.49 (1.26 to 4.93)
13.40 (6.20 to 27.50)
7.70 (5.30 to 10.90)
3.50 (1.21 to 9.99)
10.02 (6.75 to 14.89)
4.18 (2.60 to 6.73)
4.17 (2.30 to 7.59)
6.46 (4.47 to 9.32)
4.56 (3.08 to 6.74)
1.53 (0.98 to 2.37)
4.78 (3.31 to 6.92)
0.01 0.1 1 10 100
0.01 0.1 1 10 100
Case-control studies Case-control studies
Combined genotype Filaggrin R501x mutation
Odds ratio
(95% CI)
Odds ratio (random)
(95% CI)
  Marenholz 2006
w12
  Palmer (Ireland) 2006w1
  Barker 2007w10
  Lerbaek 2007
w9
  Sandilands 2007w3
  Stemmler 2007w17
  Weidinger 2007w16
  Brown 2008w19
  Brown 2008w22
  Ruether 2006w15
  Hubiche 2007w13
  Giardina 2008w14
Total (95% CI)
Test for heterogeneity: df(Q)=11,
  P=0.001, I
2=78%, z=6.871
6.65 (2.43 to 18.22)
9.22 (4.11 to 20.70)
5.85 (3.86 to 8.86)
3.39 (0.82 to 14.04)
14.05 (8.04 to 25.53)
1.31 (0.65 to 2.62)
3.59 (1.43 to 9.01)
6.19 (4.03 to 9.51)
1.51 (0.83 to 2.75)
3.59 (1.80 to 7.05)
3.20 (2.10 to 4.70)
5.93 (0.28 to 123.95)
4.32 (2.85 to 6.56)
Odds ratio
(95% CI)
Odds ratio (random)
(95% CI)
Family studies
  Marenholz 2006w12
  Palmer (Denmark) 2006
w1
  Palmer (Ireland) 2006w1
  Barker 2007w10
  Sandilands 2007w3
  Stemmler 2007w17
  Weidinger 2007w16
  Weidinger 2008w23
  Brown 2008w22
Total (95% CI)
Test for heterogeneity: df(Q)=8,
  P=0, I
2=86%, z=6.91
3.73 (1.98 to 7.02)
2.49 (1.26 to 4.93)
13.40 (6.20 to 27.50)
7.70 (5.30 to 10.90)
10.02 (6.75 to 14.89)
4.18 (2.60 to 6.73)
4.17 (2.30 to 7.59)
4.56 (3.08 to 6.74)
1.53 (0.98 to 2.37)
4.71 (3.04 to 7.31)
0.01 0.1 1 10 100
Case-control studies:
good and high quality
Odds ratio
(95% CI)
Odds ratio (random)
(95% CI)
  Palmer (Ireland) 2006w1
  Barker 2007w10
  Sandilands 2007w3
  Weidinger 2007w16
Total (95% CI)
Total events: 240 (cases),
   216 (control)
Test for heterogeneity: χ
2=7.80, df=3, P=0.05, I2=61.5%
Test for overall effect: z=10.20, P<0.001
13.40 (6.20 to 27.50)
7.70 (5.30 to 10.90)
10.02 (6.75 to 14.89)
4.17 (2.30 to 7.59)
7.98 (5.35 to 11.89)
0.01 0.1 1 10 100
Case-control studies:
hospital based cases
Odds ratio
(95% CI)
Odds ratio (random)
(95% CI)
  Marenholz 2006w12
  Morar (ECZ1 panel) 2007w8
  Morar (MRCE panel) 2007w8
  Morar (combined panel) 2007w8
  Weidinger 2006w4
  Ekelund 2008w24
  Ruether 2006w15
Total (95% CI)
Test for heterogeneity: df(Q)=6,
  P=0.457, I
2=0%, z=8.27
1.73 (1.15 to 2.59)
2.40 (1.15 to 5.02)
2.62 (1.58 to 4.33)
2.55 (1.68 to 3.86)
3.82 (1.97 to 7.42)
4.33 (1.88 to 9.94)
2.17 (1.33 to 3.56)
2.44 (1.98 to 3.02)
Odds ratio
(95% CI)
Odds ratio (random)
(95% CI)
0.01 0.1 1 10 100
0.01 0.1 1 10 100
Case-control studies
Filaggrin 2282del4 mutation
  Marenholz 2006
w12
  Palmer (Ireland) 2006w1
  Barker 2007w10
  Lerbaek 2007w9
  Sandilands 2007w3
  Stemmler 2007w17
  Weidinger 2007w16
  Brown 2008w19
  Brown 2008w22
  Ruether 2006w15
  Hubiche 2007
w13
  Giardina 2008
w14
  Howell 2007w2
Total (95% CI)
Test for heterogeneity: df(Q)=12,
  P=0.001, I
2=75.5%, z=737
2.42 (1.09 to 5.38)
16.76 (5.23 to 53.74)
7.61 (4.74 to 12.21)
2.61 (0.66 to 10.34)
8.94 (4.99 to 16.01)
1.93 (1.25 to 2.96)
5.07 (2.42 to 10.64)
4.15 (2.62 to 6.56)
2.00 (1.10 to 3.70)
7.10 (3.41 to 14.78)
11.70 (5.40 to 25.30)
1.78 (0.30 to 10.69)
2.68 (0.40 to 18.00)
4.61 (3.07 to 6.93)
Odds ratio
(95% CI)
Odds ratio (random)
(95% CI)
Family studies
  Marenholz 2006w12
  Morar (ECZ1 panel) 2007w8
  Morar (MRCE panel) 2007w8
  Morar (combined panel) 2007w8
  Weidinger 2006w4
  Ekelund 2008w24
Total (95% CI)
Test for heterogeneity: df(Q)=5,
  P=0.833, I
2=0%, z=9.25
2.13 (1.60 to 2.83)
3.00 (1.60 to 5.62)
1.88 (1.02 to 3.44)
2.38 (1.54 to 3.67)
2.43 (1.59 to 3.72)
2.22 (1.41 to 3.47)
2.27 (1.91 to 2.69)
Odds ratio
(95% CI)
Odds ratio (random)
(95% CI)
Fig 3 | Association between filaggrin combined genotype (≥1 mutation), filaggrin gene mutation R501X, and filaggrin gene mutation 2282del4 and atopic
dermatitis in case-control studies, including those of good and high quality and with hospital based cases, and family studies
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web extra table B).
w7 w18 w21 Another study
w8 was not
included in the meta-analysis because the population
comprised affected and unaffected offspring from
family panels in a case-control setting. The case-con-
trol studies included in the meta-analysis were all on
western European or North American populations.
Using a random effects model the overall odds ratio
for the combined genotype was 4.78 (3.31 to 6.92;
fig 3). Heterogeneity between the studies was signifi-
cant (P=0.001). The funnel plot showed no obvious
evidence of publication bias (see web extra fig B).
The overall odds ratio for R501X was 4.32 (2.85 to
6.56; fig 3) and for 2282del4 was 4.61 (3.07 to 6.93;
fig 3). Significant heterogeneity was observed
(I
2=78%, P<0.001, and I
2=75%, P<0.001, respec-
tively). Subgroup analysis for the combined genotype
with studies excluded that were judged to be at high
risk of bias gave an odds ratio of 4.71 (3.04 to 7.31;
fig 3), with evidence of significant heterogeneity still
showing between studies (I
2=86.0%; P<0.001).
Besides differences in quality, heterogeneity could
also be explained by differences in phenotype. Addi-
tional subgroup analyses were therefore done on the
basis of disease severity and persistence. Four studies
investigatedtheassociationbetweenthefilaggrincom-
binedgenotypeandatopicdermatitisinhospitalbased
cases.
w1 w3 w10 w16 Our assumption was that cases
recruited from hospital based dermatology clinics
probably had more severe atopic dermatitis than
those selected from the population. The overall odds
ratio for the combined genotype was 7.98 (5.35 to
11.89; fig 3); although heterogeneity was reduced it
was still significant (I
2=61.5%; P<0.05).
Two studies
w10 w19 investigated the association
between the filaggrin combined genotype and persis-
tent atopic dermatitis. Pooled data from these studies
gave an overall odds ratio of 7.01 (5.42 to 9.07; fig 4).
Heterogeneityin thissubgroupanalysiswasnotsignif-
icant (P=0.54). Three case-control studies
w16 w17 w19
showeddatafortheassociationbetweenfilaggrincom-
bined genotype and atopic dermatitis at age less than
twoyearsatonset.Onestudy
w16wasnotincludedinthe
subgroup analysis as it reported no original data for
early onset atopic dermatitis. Pooling the data for the
combined genotype from the two other studies
w17 w19
gave an overall odds ratio of 6.31 (4.68 to 8.49; fig 4).
Heterogeneity was not significant (P=0.83).
Family studies
Seven familial analyses were on western European
populations
w4 w8 w12 w15 w24 and one on a Japanese popu-
lation (see web extra table C for details).
w21 One of the
studies
w8 analysed two different family panels and pre-
sented results for the panels separately as well as com-
bined.AsthestudyonaJapanesepopulationreportedP
values only it was not included in the meta-analysis.
w21
The overall odds ratio for the combined genotype
using random effects modelling was 1.99 (1.72 to
2.31; fig 4). Heterogeneity was not significant
(P=0.21). The funnel plot did not suggest publication
bias. The overall odds ratio for R501X was 2.44 (1.98
to 3.02; fig 3) and for 2282del4 was 2.27 (1.91 to 2.69;
fig 3). Heterogeneity was not significant (P=0.46 and
P=0.83, respectively).
Cohort study
One cohort study
w20 investigated the interaction
betweenfilaggrinlossoffunctionmutationsandenvir-
onmental exposures in the development of eczema.
The data were from two independent birth cohorts
(Denmark and the United Kingdom). This study
found that filaggrin mutations increased the risk of
eczema during the first year of life: hazard ratios 2.26
(95%confidenceinterval1.27to4.00)and1.95(1.13to
3.36), respectively. The risk of eczema further
increasedwithexposuretocatsatbirthamongchildren
with filaggrin gene mutations (hazard ratios 11.11 and
3.82, respectively). This study found that exposure to
dogswasmoderatelyprotective(hazardratios0.49and
0.59, respectively).
Allergic rhinitis
People without atopic dermatitis or eczema
Three case-control studies investigated the association
between filaggrin gene defects and the risk of
  Barker 2007
w10
  Brown 2008w19
Total (95% CI)
Total events: 153 (cases),
   215 (control)
Test for heterogeneity: χ2=0.38, df=1, P=0.54, I2=0%
Test for overall effect: z=14.87, P<0.001
7.70 (5.30 to 10.90)
6.46 (4.47 to 9.32)
7.01 (5.42 to 9.07)
0.01 0.1 1 10 100
Case-control studies:
persistent atopic dermatitis
Combined genotype
Odds ratio
(95% CI)
Odds ratio (random)
(95% CI)
  Stemmler 2007
w17
  Brown 2008w19
Total (95% CI)
Total events: 128 (cases),
   113 (control)
Test for heterogeneity: χ2=0.05, df=1, P=0.83, I
2=0%
Test for overall effect: z=12.12, P<0.001
6.03 (3.62 to 10.03)
6.46 (4.47 to 9.32)
6.31 (4.68 to 8.49)
0.01 0.1 1 10 100
Case-control studies:
early onset atopic dermatitis
Odds ratio
(95% CI)
Odds ratio (random)
(95% CI)
  Marenholz 2006
w12
  Morar (ECZ1 panel) 2007w8
  Morar (MRCE panel) 2007w8
  Morar (combined panel) 2007
w8
  Weidinger 2006
w4
  Ekelund 2008
w24
Total (95% CI)
Test for heterogeneity: df(Q)=5,
  P=0.211, I2=0.907%, z=9.21
2.13 (1.68 to 2.71)
1.94 (1.27 to 2.95)
1.58 (1.12 to 2.24)
1.72 (1.32 to 2.24)
2.73 (1.87 to 3.98)
2.21 (1.50 to 3.25)
1.99 (1.72 to 2.31)
0.01 0.1 1 10 100
Family studies:
atopic dermatitis
Odds ratio
(95% CI)
Odds ratio (random)
(95% CI)
Fig 4 | Association between filaggrin combined genotype (≥1 mutation) and persistent atopic
dermatitis or early onset atopic dermatitis in case-control studies and atopic dermatitis in
family studies
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matitis (see web extra table D).
w12 w22 w23 One of these
studies
w22 reported a P value (0.66) for the combined
genotype only (not detailing any original data to allow
calculation of odds ratios). Data were pooled from the
other two studies, on German populations.
w12 w23 Using
a random effects model the overall odds ratio for the
combined genotype was 1.78 (1.16 to 2.73; fig 5).
People with atopic dermatitis or eczema
Threecase-controlstudies
w12 w16 w23andtwofamilystu-
dies
w12 w24 investigated the association between filag-
grin gene defects and the risk of developing allergic
rhinitis in people with atopic dermatitis (see web
extra table E).
Allthreecase-controlstudieswereonGermanpopu-
lations. One study
w16 reported no original data for
allergic rhinitis but only odds ratios adjusted for age
and sex (4.04, 95% confidence 2.11 to 7.72); this
study was not included in the meta-analysis. Data
were pooled from the other two case-control stu-
dies.
w12 w23 The overall estimated odds ratio for the
combined genotype was 2.84 (2.08 to 3.88; fig 5).
One family study
w12 was on a German population
and another on a Swedish population.
w24 Pooled data
forthecombinedgenotypefromthesetwostudiesgave
an overall odds ratio of 2.46 (1.61 to 3.76).
Asthma
People without atopic dermatitis or eczema
Five case-control studies
w1 w8 w12 w22 w23 and one family
study
w6 investigated the association between filaggrin
gene defects and asthma in people without atopic der-
matitis. The five case-control studies were on western
European populations, whereas the family study was
on a North American population (see web extra table
F). None of these studies showed a significant associa-
tion between filaggrin gene defects and asthma. The
familystudy
w6reportedanoddsratioforthecombined
genotype of 1.0 (0.51 to1.96; P=1.00).
Data were pooled from the case-control studies to
estimate an overall odds ratio. One study
w8 was not
included in this meta-analysis because the population
comprised affected and unaffected offspring from
family panels in a case-control setting. Another
study
w22 was also not included because it reported a P
value (0.15) for the combined genotype only. After
pooling the data from the three remaining studies,
w1
w12 w23theoveralloddsratioforthecombinedgenotype
was 1.30 (0.73 to 2.30; fig 6). Heterogeneity was not
significant (P=0.37).
People with atopic dermatitis or eczema
Sixcase-controlstudiesandsevenfamilystudiesinves-
tigated the association between filaggrin gene defects
andtheriskofdevelopingasthmainpeoplewithatopic
dermatitis. All the studiesexcept one,were onwestern
European populations; the remaining study was on a
North American population.
w6
Case-control studies
Web extra table G provides details of the included six
case-control studies. One study
w16 was not included in
the meta-analysis because the researchers reported no
original data for asthma, only odds ratios adjusted for
age and sex. Another study
w22 reported a P value of
<0.001 for the combined genotype only. Pooled data
for the combined genotype from the other four case-
control studies gave an overall odds ratio of 2.79 (1.77
to4.41;fig6).Heterogeneitywassignificant(P<0.001).
The funnel plot did not suggest publication bias (see
web extra fig C).
Family studies
Seven family studies investigated the association
between filaggrin gene defects and the risk of develop-
ing asthma in people with atopic dermatitis (see web
extra table H). One study
w8 analysed two different
family panels and presented results for each panel
separately as well as combined.
Pooled data for the combined genotype from the
family studies gave an overall odds ratio of 2.30 (1.66
to3.18;fig6).Heterogeneitywassignificant(P<0.001).
Publication bias was judged to be unlikely (see web
extra fig D).
An overall odds ratio for R501X was 2.30 (1.72 to
3.09; fig 6) and for 2282del4 was 2.82 (2.19 to 3.64;
fig 6).
DISCUSSION
In this systematic review and meta-analysis we found
that filaggrin gene defects increase the risk of
  Marenholz 2006w12
  Weidinger 2008
w23
Total (95% CI)
Test for heterogeneity: df(Q)=1,
  P=0.009, z=2.61
1.03 (0.30 to 3.20)
1.93 (1.21 to 3.05)
1.78 (1.16 to 2.73)
0.01 0.1 1 10 100
Case-control studies: no atopic eczema
Combined genotype
Odds ratio
(95% CI)
Odds ratio (random)
(95% CI)
  Marenholz 2006w12
  Weidinger 2008w23
Total (95% CI)
Test for heterogeneity: df(Q)=1,
  P=0.006, z=6.56
4.79 (2.00 to 11.60)
2.64 (1.76 to 4.00)
2.84 (2.08 to 3.88)
0.01 0.1 1 10 100
Case-control studies: atopic eczema Odds ratio
(95% CI)
Odds ratio (random)
(95% CI)
  Marenholz 2006
w12
  Ekelund 2008
w24
Total (95% CI)
Test for heterogeneity: df(Q)=1,
  P=0, I2=0%, z=4.16
3.14 (1.94 to 5.07)
2.03 (1.39 to 2.97)
2.46 (1.61 to 3.76)
0.01 0.1 1 10 100
Family studies: atopic eczema Odds ratio
(95% CI)
Odds ratio (random)
(95% CI)
Fig 5 | Association between filaggrin combined genotype (≥1 mutations) and allergic rhinitis in
people without and with atopic eczema in case-control studies and in people with atopic
eczema in family studies
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matitis, and allergic rhinitis. The risk of those with
coexistent atopic eczema developing asthma was also
increased, but not those without eczema. These find-
ingsprovidestrongsupportingevidencethat,atleastin
a subset of those with allergic problems, the filaggrin
gene defect may be the fundamental predisposing fac-
tornotonlyforthedevelopmentofeczemabutalsofor
initial sensitisation and progression of allergic disease.
The key strengths of this work include the compre-
hensiveness of the searches and our assessment for a
range of clinical and immunological outcome mea-
sures. This approach does, in theory at least, increase
thepossibilityoftype1errors,althoughwefocusedon
thepooledoddsratiosand95%confidenceintervalsof
dataobtainedfromthemeta-analysestherebyallowing
readerstojudgeforthemselvesthestrengthoftheasso-
ciations identified. As with all systematic reviews, we
may have failed to identify some studies, particularly
thosewithnegativefindings,andthismighthaveinflu-
enced our findings. Although we attempted to assess
for publication bias, we recognise that funnel plots
have relatively low power to detect such bias, particu-
larly when there are relatively few studies included in
these plots, and so these need to be interpreted with
caution.
17
Overall this work underscores the importance of
filaggringene defectsinincreasingthe riskof sensitisa-
tion and the development of a range of allergic clinical
phenotypes, most probably through exposure to aller-
gens through the skin. Our findings suggest that filag-
grin is a robust biomarker for allergic conditions.
Given the consistency of the genetic data from epide-
miological studies, we suggest that further confirma-
tory studies in eczema serve little purpose. A need
remains, however, to understand better the possible
role of filaggrin gene defects in other systemic atopic
allergicdisorderssuchasfoodallergyandanaphylaxis.
Future population based epidemiological studies
should use prospective designs categorising people
on the basis of genotype; we are aware of at least one
such study under way in the UK (S Mukhopadhyay,
personal communication, 2009). Although family
based designs are often more costly than population
based studies, greater emphasis should be placed on
using these as they have the advantage of being less
influenced by population substructure.
16 Further
work also needs to focus on the mechanisms through
which defective skin function impacts on the presenta-
tion of antigens and the possible associated immune
modulation. Useful insights into disease pathophysiol-
ogy may also be gained by studying people with filag-
grin gene defects who do not develop atopy or atopic
allergic conditions.
9 A need also exists to investigate
whetherthefilaggrinbiomarkercanbeusedtoidentify
those at high risk so that preventive measures can be
introduced such as interventions to restore the barrier
function of the skin or measures to avoid allergens in
filaggrin defective infants.
  Marenholz 2006
w12
  Palmer (Scotland) 2006w1
  Weidinger 2008w23
Total (95% CI)
Test for heterogeneity: df(Q)=2,
  P=0.374, I2=10.99%, z=0.89
2.47 (1.10 to 5.80)
0.80 (0.50 to 1.30)
1.38 (0.85 to 2.22)
1.30 (0.73 to 2.30)
0.01 0.1 1 10 100
Case-control studies: no atopic dermatitis
Combined genotype
Filaggrin mutations
Odds ratio
(95% CI)
Odds ratio (random)
(95% CI)
6.21 (2.60 to 14.80)
2.89 (2.04 to 4.11)
2.78 (0.92 to 8.42)
1.79 (1.19 to 2.68)
2.79 (1.77 to 4.41)
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Fig 6 | Association between filaggrin combined genotype (carriage of ≥1 mutation) and asthma
in people without and with atopic dermatitis in case-control studies and with atopic dermatitis
in family studies, filaggrin R501X mutation and asthma in people with atopic dermatitis in
family studies, and filaggrin 2282del4 mutation and asthma in people with atopic dermatitis in
family studies
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WHAT IS ALREADY KNOWN ON THIS TOPIC
Atopic allergic disorders affect up to a third of people worldwide
Eczema is often the herald condition in those with allergic conditions, typically beginning in
the first year of life
Filaggrin gene defects, present in up to one in 10 western Europeans and North Americans,
are possible predisposing factors in the development of atopic eczema
WHAT THIS STUDY ADDS
Filaggrin gene defects increase the risk of allergic sensitisation, suggesting that defective
function of the skin barrier may be fundamental in people with allergic disorders
Filaggrin gene defects are associated with a significantly increased risk of atopic eczema,
allergic rhinitis, and asthma in people with eczema
Interventions to restore the barrier function of the skin or measures to avoid allergens in
filaggrin defective infants need investigation
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